Navigation Links
Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association
Date:5/20/2008

clinical trials; risks associated with being a manufacturer of some of our products; risks associated with contractual agreements, particularly for the manufacture and co-promotion of SANCTURA and SANCTURA XR and the manufacture of NEBIDO, VANTAS, SUPPRELIN LA and VALSTAR; reliance on intellectual property and having limited patents and proprietary rights; dependence on market exclusivity, changes in reimbursement policies and/or rates for SANCTURA, SANCTURA XR, VANTAS, SUPPRELIN LA, DELATESTRYL and any future products; acceptance by the healthcare community of our approved products and product candidates; uncertainties relating to clinical trials, regulatory approval and commercialization of our products, particularly SANCTURA XR, NEBIDO, and VALSTAR; product liability and insurance uncertainties; risks relating to the Redux-related litigation; need for additional funds and corporate partners, including for the development of our products; history of operating losses and expectation of future losses; uncertainties relating to controls over financial reporting; difficulties in managing our growth; valuation of our Common Stock; risks related to repayment of debts; risks related to increased leverage; general worldwide economic conditions and related uncertainties; and other risks. Indevus undertakes no obligation to publicly update any forward- looking statement, whether as a result of new information, future events or otherwise.

Michael W. Rogers Brooke D. Wagner

Executive Vice President and CFO VP, Corp. Communications

(781) 861-8444 (781) 402-3410


'/>"/>
SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Indevus Pharmaceuticals Provides Update on PRO 2000 Program
2. Indevus Reports Additional Positive Phase III Trial Data for NEBIDO(R)
3. Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial
4. Indevus Announces Submission of New Drug Application
5. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
6. Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference
7. Napo Presents at ISPOR Meeting in Toronto
8. Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session
9. Dr. Calvin Grant Presents Results from Xibrom(TM) Combination Therapy with Lucentis(R) at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO)
10. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
11. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... -- Research and Markets ( ... "Veterinary Pharmaceutical Submissions in the EU (London, ... their offering. This practical two-day course ... parts of the application for marketing authorisation for ... authorisation is sought in the European Union, including ...
(Date:9/4/2015)... 4, 2015 Hutchison China ... Hutchison MediPharma Limited ("HMP"), its drug R&D subsidiary, ... proof-of-concept ("POC") trial of fruquintinib in patients with ... China .  The top-line results ... the primary efficacy endpoint of progression free survival ...
(Date:9/3/2015)... Sept. 3, 2015 With a population of ... country and therefore also its single largest potential market ... China has led all major world economies in the ... expenditures, and government health expenditures. As an in vitro ... markets of the United States, western European countries, and ...
Breaking Medicine Technology:Veterinary Pharmaceutical Submissions in the EU: Two day Course - London, UK - December 7-8, 2015 2Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 2Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 3IVD in China 2IVD in China 3IVD in China 4IVD in China 5IVD in China 6IVD in China 7IVD in China 8IVD in China 9IVD in China 10IVD in China 11IVD in China 12IVD in China 13
... (OTC Bulletin Board: ACUR) (the "Company") today announced ... "Agreement"), with an,investor group comprised of Vivo Ventures ... L.P., GCE Holdings LLC and certain individual investors,(the ... Units ("Units") at a price of $1.08 per ...
... 20 Ranbaxy Pharmaceuticals Inc.,(RPI), a wholly owned ... RLL has received approval from the U.S. Food ... and,Acetaminophen Tablets USP, 7.5 mg/750 mg, 10 mg/500 ... The Office of Generic Drugs, U.S. Food and ...
Cached Medicine Technology:Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate 2Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate 3Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP 2
(Date:9/4/2015)... (PRWEB) , ... September 04, 2015 , ... With TransCel ... a mouse all within Final Cut Pro X. With TransCel users have full control ... frame width, background color, speed method, frame color, inner color, text, and more. With ...
(Date:9/4/2015)... ... , ... IVF New England, one of the largest and most successful fertility ... Manchester for women who wish to learn more about their fertility and egg freezing. ... 827 Elm Street, Manchester, NH from 6PM to 7PM , This hip, casual and ...
(Date:9/4/2015)... ... September 04, 2015 , ... A Union ... Project. Core Compassion Project is a non-profit organization dedicated to offering Pilates ... effects of cancer treatments and recover their mobility, strength, and range of motion ...
(Date:9/4/2015)... Maui HI (PRWEB) , ... September 04, 2015 , ... ... the best ways for couples to explore, revitalize and strengthen their ‘couple-ness,’” says ... and his team at Four Seasons Resort Maui, the island’s only Forbes Five Star ...
(Date:9/4/2015)... ... September 04, 2015 , ... The USC Eye Institute is proud ... nationwide by Doximity. Faculty, residents and staff are honored to have contributed to ... quality of our ophthalmology residency program. Our faculty places a high priority on our ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios Releases TransCel, a New FCPX Transition 2Health News:IVF New England to Host ManchVegas New Hampshire Fertility Happy Hour on October 15, 2015 in Manchester for Women Who Wish to Learn More About Fertility and Egg Freezing 2Health News:Girl’s Night Out to Benefit Core Compassion Project, Located at the Beautiful, Morning Glory Farm 2Health News:Couples Season at Four Seasons Resort Maui Begins This Week With Best Hotel Rates of the Year through November 2Health News:Couples Season at Four Seasons Resort Maui Begins This Week With Best Hotel Rates of the Year through November 3Health News:USC Ophthalmology Residency Program Ranked in Top 10 by Doximity 2Health News:USC Ophthalmology Residency Program Ranked in Top 10 by Doximity 3
... Patients with obstructive sleep apnea who undergo surgery to ... are less drowsy during the day, according to a new ... The study finds surgery greatly reduces daytime sleepiness a ... airway is partially or completely blocked during sleep when ...
... Research and Policy of The Research Institute at Nationwide ... 6 to 18 years old and found that an ... from 1994 through 2007, for an average of more ... period, the annual number of running-related injuries increased 34 ...
... News) -- Electroshock devices, currently classified by the U.S. Food ... severe depression, could be downgraded to medium risk this year. ... to discuss reclassifying the devices, which would pave the way ... illnesses. , , A medium-risk classification would put the devices ...
... January 27, 2011 -- A new study by ... physicians who give second opinions may be influenced by ... In the study, the researchers presented hypothetical scenarios with ... of orthopedic surgeons and neurologists. Some were told that ...
... food when they are pregnant? Is it just certain groups? ... study from the Norwegian Institute of Public Health provides some ... Mother and Child Cohort Study. "We know little ... goal of this study was to find out what is ...
... HealthDay Reporter , WEDNESDAY, Jan. 26 (HealthDay News) -- The ... implants may be linked to a heightened risk for a ... of cases that have been reported in recent years. ... may be linked to anaplastic large cell lymphoma (ALCL), which ...
Cached Medicine News:Health News:Surgery for obstructive sleep apnea reduces daytime drowsiness 2Health News:FDA May Ease Up on Electroshock Devices 2Health News:FDA May Ease Up on Electroshock Devices 3Health News:Ben-Gurion U. researchers determine that a first medical opinion can influence the second 2Health News:Organic food in pregnancy -- new study 2Health News:FDA Says Breast Implants Linked to Rare Cancer 2Health News:FDA Says Breast Implants Linked to Rare Cancer 3Health News:FDA Says Breast Implants Linked to Rare Cancer 4
Microwell EIA for detection of Calcitonin...
... with Stainless Steel Staples for use with ... disposable loading unit, the LDS-2™ instrument places ... tissue within the cartridge jaw and the ... two closed clips. The instrument is activated ...
The ALLPORT and ALLPORT LS Endoscopic Rotating Multiple Clip Appliers have application for use on tubular structures or vessels. The tissue being ligated should be consistent with the size of the cli...
... Ligating Clip Applier is a reusable instrument ... and clips are designed to offer a ... structures where an absorbable ligating device is ... clip at the ligation site and facilitates ...
Medicine Products: